pimonidazole has been researched along with mk 2206 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bussink, J; Grénman, R; Iida, M; Kaanders, JH; Span, PN; Stegeman, H; van der Kogel, AJ; Verheijen, MM; Waaijer, SJ; Wheeler, DL | 1 |
1 other study(ies) available for pimonidazole and mk 2206
Article | Year |
---|---|
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.
Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; ErbB Receptors; Fluorescent Antibody Technique; Head and Neck Neoplasms; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |